| Ytd | -6.95% | |
| 1y | 16.78% |
| Open | 1.67 | Prev Close | 1.68 | Low | 1.66 | High | 1.81 | Mkt Cap | 540.45M |
| Vol | 5.00M | Avg Vol | 6.30M | EPS | -0.41 | P/E | N/A | Forward P/E | -2.84 |
| Beta | 2.01 | Short Ratio | 4.46 | Inst. Own | 84.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.45 | 200-d Avg | 1.69 | 1yr Est | 3.02 |
PACB News
Pacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50
Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level predict
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
The protocol will be formally presented at the upcoming American Association for Cancer Research (AA
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to U
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today ann
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, ann
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overw
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
Ark Invest made significant trades involving PLTR, AMD, PACB, and DASH. They sold Palantir and bough
The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to d
MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a
PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long-read sequencing solut
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.13) per share which beat the anal
PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, toda
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic c
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic c
Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomi
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and
Organization's 6,000-genome effort will power global ALS research through detailed long-read seq
